The most common grade @ or worse adverse events were neutropenia ( @ patients -LSB- @ % -RSB- in the ramucirumab group vs @ -LSB- @ % -RSB- in the control group ) , febrile neutropenia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , fatigue ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , leucopenia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , and hypertension ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) .